Presentationer och intervjuer

  Presentation Media Date

Follow us – Stay updated

22 november, 2021

AlzeCure Pharma – Redeye Life Science Day

11 november, 2021

AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.

22 oktober, 2021

Alzecure presents at Healthcare Innovation Summit

7 oktober, 2021

Alzecure Pharma – Naventus Life Science Summit

29 september, 2021

Aktiespararna intervjuar VD Martin Jönsson – senaste kvartalsrapporten och framtidsutsikterna

20 september, 2021

AlzeCure Pharma – Aktiedagen Stockholm

7 september, 2021

Strategy Update on Alzheimer’s Disease & NeuroRestore

1 september, 2021

Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD

1 september, 2021

Company Overview & Vision by Martin Jönsson CEO

1 september, 2021

NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research

1 september, 2021

Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer

1 september, 2021

ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021

29 juli, 2021

Om AlzeCures uppkomst och utveckling – Ett embryo som kan bli något stort – med Bengt Winblad, professor, senior vid Karolinska Institutet.

11 juni, 2021

Om Alzstatin och läkemedel vid Alzheimers sjukdom – med Bengt Winblad, professor, senior vid Karolinska Institutet.

11 juni, 2021

Om att drabbas av Alzheimers sjukdom, diagnostik, vården idag samt framtida behov – med Bengt Winblad, professor, senior vid Karolinska Institutet.

11 juni, 2021

Negativa allosteriska modulatorer av TrkA för behandling av smärta – Vetenskaplig presentation på smärtkonferensen IASP, juni 2021

11 juni, 2021

ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Vetenskaplig presentation på smärtkonferensen IASP, juni 2021

9 juni, 2021

Alzecure: VD Martin Jönsson presenterar på Redeye Growth Day

7 juni, 2021

CEO Martin Jönsson after the company’s annual meeting

17 maj, 2021

TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, 11 Maj, 2021

11 maj, 2021

ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, 11 Maj, 2021

11 maj, 2021

Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, 11 Maj, 2021

11 maj, 2021

Company overview and goals by CEO Martin Jönsson, 11 Maj, 2021

11 maj, 2021

Update on Progress in the Painless Platform, May 11, 2021

11 maj 2021